Stick With LAMA Inhalers Instead of Nebulized Yupelri for Most COPD Patients

April 2019

You'll see Yupelri (yoo-PEL-ree, revefenacin), the first ONCE-daily nebulized long-acting muscarinic antagonist (LAMA) for COPD.

It will have an edge over TWICE-daily Lonhala Magnair (glycopyrrolate)...the only other nebulized LAMA.

Yupelri is given via a standard nebulizer. Lonhala requires its own Magnair nebulizer...which can't be used to nebulize other meds.

Get concise, unbiased advice for effective drug therapy, plus CE/CME

Prescriber Insights: APRN includes:

  • Cutting-edge advice about new medications and how they fit into practice
  • Unbiased, evidence-based, 100% free of financial support from the pharma industry written by your peers
  • Side-by-side comparisons of drugs by class or disease state, plus FAQs, pros/cons, and simple recommendations

Already a subscriber? Log in

Volume pricing available. Get a quote